Biomarkers of Everolimus Sensitivity in Hormone Receptor-Positive Breast Cancer

Activation of the mammalian target of rapamycin (mTOR) signaling pathway is an important mechanism of resistance to endocrine therapy in breast cancer. Everolimus, an mTOR inhibitor, has been shown to increase the efficacy of endocrine therapy and overcome resistance to endocrine therapies. Clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Yi, Zongbi, Ma, Fei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Breast Cancer Society 2017
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5743990/
https://www.ncbi.nlm.nih.gov/pubmed/29285035
http://dx.doi.org/10.4048/jbc.2017.20.4.321

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5743990/
https://www.ncbi.nlm.nih.gov/pubmed/29285035
http://dx.doi.org/10.4048/jbc.2017.20.4.321

Ejemplares similares